KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to $8.8 million.

  • Neogenomics' Depreciation and Depletion fell 852.13% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.1 million, marking a year-over-year decrease of 441.68%. This contributed to the annual value of $39.1 million for FY2024, which is 440.85% up from last year.
  • Neogenomics' Depreciation and Depletion amounted to $8.8 million in Q3 2025, which was down 852.13% from $9.1 million recorded in Q2 2025.
  • Neogenomics' 5-year Depreciation and Depletion high stood at $9.9 million for Q1 2024, and its period low was $6.7 million during Q1 2021.
  • Moreover, its 5-year median value for Depreciation and Depletion was $9.1 million (2025), whereas its average is $8.9 million.
  • As far as peak fluctuations go, Neogenomics' Depreciation and Depletion skyrocketed by 2567.37% in 2022, and later tumbled by 852.13% in 2025.
  • Quarter analysis of 5 years shows Neogenomics' Depreciation and Depletion stood at $8.4 million in 2021, then grew by 13.04% to $9.5 million in 2022, then rose by 1.06% to $9.6 million in 2023, then increased by 2.6% to $9.8 million in 2024, then dropped by 10.42% to $8.8 million in 2025.
  • Its last three reported values are $8.8 million in Q3 2025, $9.1 million for Q2 2025, and $9.4 million during Q1 2025.